Precision oncology has long promised a future in which each patient’s tumor is read like a molecular instruction manual, with treatments selected to match the specific genetic faults driving the disease. Yet the promise has repeatedly stumbled in clinical trials, where aberration-guided therapies have too often failed to deliver the